ITTO20010008A0 - Formulazione farmaceutica - Google Patents

Formulazione farmaceutica

Info

Publication number
ITTO20010008A0
ITTO20010008A0 IT2001TO000008A ITTO20010008A ITTO20010008A0 IT TO20010008 A0 ITTO20010008 A0 IT TO20010008A0 IT 2001TO000008 A IT2001TO000008 A IT 2001TO000008A IT TO20010008 A ITTO20010008 A IT TO20010008A IT TO20010008 A0 ITTO20010008 A0 IT TO20010008A0
Authority
IT
Italy
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
IT2001TO000008A
Other languages
English (en)
Inventor
John Raymond Evans
Rosalind Ursula Grundy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITTO20010008(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ITTO20010008A0 publication Critical patent/ITTO20010008A0/it
Publication of ITTO20010008A1 publication Critical patent/ITTO20010008A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT2001TO000008A 2000-01-10 2001-01-10 Formulazione farmaceutica ITTO20010008A1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation

Publications (2)

Publication Number Publication Date
ITTO20010008A0 true ITTO20010008A0 (it) 2001-01-10
ITTO20010008A1 ITTO20010008A1 (it) 2002-07-10

Family

ID=26243352

Family Applications (2)

Application Number Title Priority Date Filing Date
IT000005A ITTO20010005A1 (it) 2000-01-10 2001-01-09 Formulazione farmaceutica.
IT2001TO000008A ITTO20010008A1 (it) 2000-01-10 2001-01-10 Formulazione farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IT000005A ITTO20010005A1 (it) 2000-01-10 2001-01-09 Formulazione farmaceutica.

Country Status (41)

Country Link
US (5) US20030125387A1 (it)
EP (4) EP2286818B1 (it)
JP (3) JP3713237B2 (it)
KR (1) KR100802366B1 (it)
CN (1) CN1222292C (it)
AR (1) AR027510A1 (it)
AT (1) ATE306928T1 (it)
AU (1) AU762080B2 (it)
BE (1) BE1013477A3 (it)
BG (1) BG65776B1 (it)
BR (1) BR0107445B1 (it)
CA (1) CA2351004C (it)
CH (1) CH696260A5 (it)
CO (1) CO5280206A1 (it)
CY (1) CY1116520T1 (it)
CZ (1) CZ304689B6 (it)
DE (2) DE60114145T3 (it)
DK (2) DK1250138T4 (it)
EE (1) EE05421B1 (it)
EG (1) EG24074A (it)
ES (3) ES2248272T5 (it)
FR (1) FR2803516B1 (it)
GB (3) GB0000313D0 (it)
HK (2) HK1052884B (it)
HU (1) HU230162B1 (it)
IL (2) IL150230A0 (it)
IS (1) IS2932B (it)
IT (2) ITTO20010005A1 (it)
MX (1) MXPA02006698A (it)
MY (1) MY118583A (it)
NL (1) NL1017075C2 (it)
NO (2) NO336286B1 (it)
PL (1) PL202525B1 (it)
PT (2) PT2266573E (it)
RU (1) RU2263507C9 (it)
SI (2) SI1250138T2 (it)
SK (1) SK287221B6 (it)
TW (1) TWI259086B (it)
UA (1) UA75879C2 (it)
WO (1) WO2001051056A1 (it)
ZA (1) ZA200204165B (it)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CA2453111A1 (en) * 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
EP1928469A4 (en) * 2005-09-26 2008-12-31 Hospira Australia Pty Ltd Fulvestrant FORMULATION
RU2338538C1 (ru) * 2007-02-09 2008-11-20 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотензивное средство
CA2716576A1 (en) 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
CN102600073B (zh) 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
WO2013153559A1 (en) * 2012-04-09 2013-10-17 Scidose, Llc Fulvestrant formulations
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN104936971B (zh) 2013-04-18 2017-10-13 西安力邦医药科技有限责任公司 具有抗癌活性的7‑α‑[9‑(4，4，5，5，5‑五氟戊基亚硫酰基)壬基]‑雌甾‑1，3，5(10)‑三烯‑3，17β‑二醇的酯类衍生物及其制备方法
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
EP3041512A4 (en) * 2013-09-06 2017-05-10 Ahmed, Salah U. Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
WO2017064639A1 (en) 2015-10-13 2017-04-20 Themis Medicare Limited Fulvestrant compositions
ES2935125T3 (es) 2015-12-09 2023-03-01 Univ Illinois Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3441073B1 (en) * 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (en) * 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
WO2019224790A2 (en) 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
US12240869B2 (en) 2018-11-01 2025-03-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3138058A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
US12377049B2 (en) 2019-12-11 2025-08-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CR20230283A (es) 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4525926A1 (en) 2022-05-20 2025-03-26 Novartis AG Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2025517430A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202539634A (zh) 2024-04-10 2025-10-16 瑞士商諾華公司 Ｐａｎｒａｓ抑制劑及其使用方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) † 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (it) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) † 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
KR100499438B1 (ko) 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
WO2000059473A1 (en) 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
CA2453111A1 (en) 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
ES2186517B2 (es) 2004-03-16
CA2351004A1 (en) 2001-07-10
PL356030A1 (en) 2004-06-14
NL1017075A1 (nl) 2001-07-11
DE60114145T3 (de) 2015-09-17
US20030125387A1 (en) 2003-07-03
ATE306928T1 (de) 2005-11-15
SI1250138T1 (sl) 2006-02-28
RU2263507C2 (ru) 2005-11-10
HK1150021A1 (en) 2011-10-28
DK1250138T3 (da) 2006-01-23
AU762080B2 (en) 2003-06-19
MXPA02006698A (es) 2002-09-30
ITTO20010005A1 (it) 2001-07-11
EP2266573A1 (en) 2010-12-29
EG24074A (en) 2008-05-11
HK1049286B (en) 2006-04-07
US20100152149A1 (en) 2010-06-17
CN1394141A (zh) 2003-01-29
DK1250138T4 (en) 2015-07-27
HK1049286A1 (en) 2003-05-09
HUP0204137A2 (hu) 2003-04-28
AR027510A1 (es) 2003-04-02
US20050043285A1 (en) 2005-02-24
US8466139B2 (en) 2013-06-18
DE60114145D1 (de) 2006-03-02
RU2263507C9 (ru) 2020-07-28
BE1013477A3 (fr) 2002-02-05
FR2803516B1 (fr) 2003-03-28
HUP0204137A3 (en) 2005-03-29
EP1250138B1 (en) 2005-10-19
JP2004107353A (ja) 2004-04-08
US7456160B2 (en) 2008-11-25
EP2266573B1 (en) 2015-06-17
UA75879C2 (en) 2006-06-15
US6774122B2 (en) 2004-08-10
DK2266573T3 (en) 2015-07-20
US20120329766A1 (en) 2012-12-27
IS2932B (is) 2015-12-15
BG106833A (en) 2003-03-31
EP1250138A1 (en) 2002-10-23
MY118583A (en) 2004-12-31
ES2248272T3 (es) 2006-03-16
CO5280206A1 (es) 2003-05-30
IS6454A (is) 2002-07-03
BR0107445B1 (pt) 2012-10-30
NO20023227D0 (no) 2002-07-03
CN1222292C (zh) 2005-10-12
NO337329B1 (no) 2016-03-14
SK9842002A3 (en) 2003-05-02
NO20150741L (no) 2002-07-03
KR20020073499A (ko) 2002-09-26
NL1017075C2 (nl) 2001-09-25
SI1250138T2 (sl) 2015-09-30
JP3713237B2 (ja) 2005-11-09
BG65776B1 (bg) 2009-11-30
CY1116520T1 (el) 2017-03-15
AU2386301A (en) 2001-07-24
SK287221B6 (sk) 2010-03-08
ES2543384T3 (es) 2015-08-18
DE60114145T2 (de) 2006-07-13
EP1250138B2 (en) 2015-07-08
NO336286B1 (no) 2015-07-13
RU2002121507A (ru) 2004-03-20
GB0100407D0 (en) 2001-02-21
PL202525B1 (pl) 2009-07-31
ES2248272T5 (es) 2015-08-19
PT102548A (pt) 2001-07-31
HU230162B1 (hu) 2015-09-28
CA2351004C (en) 2003-02-18
GB2359254B (en) 2002-06-19
IL150230A0 (en) 2002-12-01
GB2359254A (en) 2001-08-22
NO20023227L (no) 2002-07-03
IL150230A (en) 2006-10-31
EP2286818B1 (en) 2020-03-18
EP1669073A3 (en) 2008-03-19
JP2003519659A (ja) 2003-06-24
HK1052884A1 (en) 2003-10-03
DE10100779A1 (de) 2001-07-26
ZA200204165B (en) 2003-10-29
CZ304689B6 (cs) 2014-09-03
EE05421B1 (et) 2011-06-15
BR0107445A (pt) 2002-09-17
EP1669073A2 (en) 2006-06-14
KR100802366B1 (ko) 2008-02-13
SI2266573T1 (sl) 2015-08-31
WO2001051056A1 (en) 2001-07-19
FR2803516A1 (fr) 2001-07-13
EP2286818A1 (en) 2011-02-23
ITTO20010008A1 (it) 2002-07-10
US8329680B2 (en) 2012-12-11
CZ20022384A3 (cs) 2002-09-11
EE200200387A (et) 2003-10-15
TWI259086B (en) 2006-08-01
ITTO20010005A0 (it) 2001-01-09
GB0000313D0 (en) 2000-03-01
HK1052884B (zh) 2006-07-14
ES2186517A1 (es) 2003-05-01
JP2011190275A (ja) 2011-09-29
US20010020016A1 (en) 2001-09-06
GB0008837D0 (en) 2000-05-31
CH696260A5 (de) 2007-03-15
PT2266573E (pt) 2015-07-28

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20033785D0 (no) Farmasöytisk formulering
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20033556L (no) Farmasöytiske formuleringer
DK1524266T3 (da) Farmaceutisk sammensætning
ITMI20010748A0 (it) Composizioni farmaceutiche
EE05376B1 (et) Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20025450L (no) Ny farmasöytisk sammensetning
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20035627D0 (no) Farmasöytisk formulering
NO20015670L (no) Forbedrede farmasöytiske formuleringer
NO20026123L (no) Farmasöytiske sammensetninger
NO20031095D0 (no) Farmasöytiske sammensetninger
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
ID30032A (id) Formulasi farmasi
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering
EE200200689A (et) Ravimkoostised
NO20041236L (no) Farmasoytisk formulering
SE0102069D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation